Ticker Details
Agenus Inc. Agenus Inc along with its subsidiaries is a pharmaceutical company. It is engaged in discovery and development of revolutionary new treatments that engage the body's immune system to benefit patients suffering from cancer.
IPO Date:	February 4, 2000
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$170.87M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.12 | 3.45%
Avg Daily Range (30 D):	$0.16 | 4.45%
Avg Daily Range (90 D):	$0.13 | 3.75%

Institutional Daily Volume
Avg Daily Volume:	.48M
Avg Daily Volume (30 D):	.64M
Avg Daily Volume (90 D):	.63M

Trade Size
Avg Trade Size (Sh.):	95
Avg Trade Size (Sh.) (30 D):	127
Avg Trade Size (Sh.) (90 D):	131

Institutional Trades
Total Institutional Trades:	1,262
Avg Institutional Trade:	$1.65M
Avg Institutional Trade (30 D):	$.56M
Avg Institutional Trade (90 D):	$.53M
Avg Institutional Trade Volume:	.03M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.76M
Avg Closing Trade (30 D):	$.56M
Avg Closing Trade (90 D):	$.56M
Avg Closing Volume:	39.04K

News

Feb 18, 2026 @ 4:00 PM CTLA-4 Inhibitors Competitive Landscape Research R... Source: Researchandmarkets.Com

Jan 5, 2026 @ 11:04 PM Agenus (AGEN) Q3 2024 Earnings Call Transcript Source: Motley Fool Transcribing

Aug 28, 2025 @ 2:44 PM FDA Tightens Survival Standards as Cancer Drug Pip... Source: Prnewswire

Aug 18, 2025 @ 5:00 PM PD-(L)1 Inhibitors Market Set to Surge During the ... Source: Delveinsight

Aug 13, 2025 @ 2:00 PM U.S. Pharmaceutical CDMO Market Valuation to Surpa... Source: Towards Healthcare

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$	$-.37	$
Diluted EPS	$	$-.37	$
Revenue	$114.2M	$34.2M	$114.2M
Gross Profit	$113.17M	$34.2M	$113.17M
Net Income / Loss	$-3.08M	$-10.61M	$-3.08M
Operating Income / Loss	$-20.17M	$14.4M	$-20.17M
Cost of Revenue	$1.02M	$M	$1.02M
Net Cash Flow	$-39.41M	$-.46M	$-39.41M
PE Ratio

Splits
Apr 12, 2024	1:20
Oct 03, 2011	1:6